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Abstract
Background: Flavivirus cross-reactive antibodies in human sera interfere with the definitive identification of
dengue virus (DENV) infections especially in areas with multiple co-circulating flaviviruses. Use of DENV envelope
domain-III (EDIII) can partially resolve the problem. This study has examined the effect of (i) incorporating the EDIIIs
of four DENV serotypes into a single chimeric antigen, and (ii) immobilizing the antigen through specific
interaction on the sensitivity and specificity of anti-DENV antibody detection.
Methods: A sera panel (n = 164) was assembled and characterized using commercial kits for infection by DENV
and a host of other pathogens. Anti-DENV antibodies of both IgM and IgG classes in this panel were detected in
indirect ELISAs using a mixture of monovalent EDIIIs, a chimeric EDIII-based tetravalent antigen, EDIII-T, and a
biotinylated version of the latter as coating antigens. The sensitivity and specificity of these assays were compared
to those obtained using the PanBio Dengue IgG/IgM ELISAs.
Results: The performance of dengue IgG and IgM indirect ELISAs, using either a physical mixture of four EDIIIs or
the single chimeric EDIII-T antigen, were comparable. Coating of a biotinylated version of the tetravalent antigen
on streptavidin plates enhanced sensitivity without compromising specificity.
Conclusions: The incorporation of the EDIIIs of the four DENV serotypes into a single chimeric antigen did not
adversely affect assay outcome in indirect ELISAs. Oriented, rather than random, immobilization of the tetravalent
antigen enhanced sensitivity of detection of anti-DENV antibodies with retention of 100% specificity.
Background
Dengue viruses (DENV), of which there are four sero-
types (DENV-1,-2,-3 and -4), are mosquito-borne flavi-
viruses of the Flaviviridae family, which also includes
other members, such as yellow fever virus, Japanese ence-
phalitis virus, West Nile virus and tick-borne encephalitis
virus (TBEV) [1]. Currently, there is no vaccine to pre-
vent or a drug to treat DENV infection, which poses a
public health threat to nearly half the global population
[2]. In this scenario, the availability of reliable diagnostic
tools assumes great importance in clinical management,
surveillance and outbreak investigations. As DENVs
share antigenic similarities with other flaviviruses and
tend to co-circulate with some of them in many endemic
areas, the unambiguous detection of anti-DENV antibo-
dies using currently available commercial kits, which use
mixtures of inactivated virus preparations or recombi-
nant envelope proteins for antibody detection, is often
not possible [2].
Efforts to eliminate the problem of cross-reactivity
have begun to focus on the utility of DENV envelope
protein domain III (EDIII), as a diagnostic intermediate
of high specificity [3-5]. As this domain contains both
serotype-specific as well as DENV complex-specific epi-
topes [6], it is necessary to utilize EDIIIs of all four
DENV serotypes to detect anti-DENV antibodies.
Recently, we designed a single recombinant chimeric
* Correspondence: navin@icgeb.res.in
Recombinant Gene Products Group, International Centre for Genetic
Engineering & Biotechnology, New Delhi, India
Batra et al. BMC Infectious Diseases 2011, 11:64
http://www.biomedcentral.com/1471-2334/11/64
© 2011 Batra et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
tetravalent antigen, EDIII-T, by linking the EDIIIs of the
four DENV serotypes [5]. However, the sensitivity of
this antigen in detecting anti-DENV antibodies in
enzyme linked immunosorbent assays (ELISA) was not
as high as that of the reference assays. This may have
been the result of unavailability of some of the epitopes,
arising either from the incorporation of the EDIIIs into
a tetravalent design, or, due to random adsorption of
the EDIII-T antigen on the polystyrene surface during
the performance of ELISAs. To address these issues we
have expressed and purified four monovalent DENV
EDIII antigens [7,8] and a biotinylated version of EDIII-
T antigen (b-EDIII-T) [8], for oriented immobilization
on a streptavidin-coated surface.
The major aims of this study were to (i) compare the
performance of single EDIII-T antigen with a physical
mixture of monovalent EDIIIs corresponding to the four
DENV serotypes; and, (ii) evaluate if oriented immobili-
zation of the tetravalent antigen influences the sen-
sitivity of detection of both IgG and IgM classes of
anti-DENV antibodies, in indirect ELISA. We report
here the outcome of a parallel evaluation of a physical
mixture of EDIIIs, EDIII-T and b-EDIII-T as diagnostic
antigens in ELISAs for the detection of anti-DENV anti-
bodies in human sera.
Methods
Study design
A panel of 164 sera obtained from both dengue-endemic
and non-endemic regions was pre-screened for evidence
of infection by DENV, TBEV and a variety of non-
flavivirus pathogens including Chikungunya virus, Plas-
modium, Leptospira, and Salmonella using commercially
available kits. This panel was used in indirect ELISAs to
evaluate the performance of a mixture of monovalent
EDIIIs, EDIII-T and b-EDIII-T as diagnostic reagents in
detecting anti-DENV antibodies.
Materials
Goat anti-human IgG (g-chain specific)-horseradish per-
oxidase (HRP), and goat anti-human IgM (μ-chain spe-
cific)-HRP conjugates were purchased from Calbiochem
(La Jolla, CA, USA). HRP substrate 3, 3’, 5, 5’-Tetra-
methylbenzidine (TMB) was from Sigma-Aldrich (St.
Louis, MO, USA). Maxisorp polystyrene ELISA plates
and immobilizer streptavidin ELISA plates were from
Nunc-Thermo fisher scientific (Roskilde, Denmark).
Dengue IgG/IgM capture ELISA test was from PanBio
Diagnostics (Brisbane, Australia) and TBEV IgG/IgM
ELISA was from Virion/Serion GmbH (Würzburg,
Germany). The Advantage Pan Malaria Card test for
Plasmodium LDH antigen and the Lepto IgM micro-
ELISA test for Leptospira interrogans antibodies were
from J. Mitra & Company Ltd. (New Delhi, India). The
Typhi-Dot test for Salmonella typhi antibodies was from
MBDr Diagnostics Sdn Bhd (Selangor, Malaysia) and the
Insight Chik V rapid test for chikungunya antibodies
was from Tulip Diagnostics Ltd. (Goa, India).
Human sera
The human sera samples (n = 164) used in this study
were from hospitals in India and Finland. Sera were
drawn in the early symptomatic phase after informed
written consent of the patients. Ethical permissions for
the collection of blood samples were obtained from the
ethical committees of the respective hospitals. All sera
were pre-screened for anti-DENV antibodies using the
PanBio Dengue IgG/IgM capture ELISA test. Eighty
samples scored positive and 84 scored negative for
DENV IgG whereas 81 samples scored positive and 83
scored negative for DENV IgM antibodies. Of the
DENV IgM-/IgG- sera samples (n = 72), there was evi-
dence of infection by TBEV (n = 18), Plasmodium (n =
6), Leptospira interrogans (n = 5), Salmonella typhi (n =
6) and Chikungunya virus (n = 4).
Recombinant EDIII antigens
The monovalent EDIIIs antigens used in this study, cor-
responding to the four DENV serotypes, each contain
121 amino acid (aa) residues spanning DENV envelope
aa296-aa416. Their expression and purification have
been reported earlier [7,8]. The design of the tetravalent
antigen EDIII-T containing the EDIIIs of the four
DENV serotypes, linked in tandem, its expression and
purification have been described previously [5]. To pro-
duce the biotinylated tetravalent antigen b-EDIII-T, we
used an in vivo method wherein the biotinyl moiety is
added to a specific site enzymatically [8]. The chemical
method which tends to add the biotinyl moiety in a ran-
dom fashion to available acceptor groups is not quite
suitable for achieving uniform and oriented binding on
streptavidin coated surfaces. In order to carry out site-
specific enzymatic biotinylation of the EDIII-T antigen
in vivo, a biotin acceptor peptide (BAP) was cloned in
frame with the amino terminus of the EDIII-T antigen
and co-expressed with biotin ligase in E. coli. The engi-
neered BAP moiety of the recombinant tetravalent anti-
gen serves as the substrate for biotin ligase resulting in
the production of in vivo biotinylated tetravalent anti-
gen, b-EDIII-T [8].
IgG and IgM indirect ELISA
Polystyrene ELISA plate wells were coated either with
100 μl of EDIII-T (3 μg/ml), b-EDIII-T (3 μg/ml) or a
mixture of four EDIII antigens (0.75 μg/ml of each
EDIII) in 0.1 M carbonate buffer, pH 9.5, and incubated
overnight at 4°C. The wells were blocked with 200 μl of
blocking solution (4% skim milk in 1x PBS, pH 7.2) at
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37°C for 2 hours and washed 3x with 1x PBS, pH 7.2/1%
Tween 20/0.5 M KCl. For DENV specific IgG detection
in sera, washed wells were incubated with 100 μl patient
serum diluted 1:100 in IgG assay diluent (1x PBS, pH
8.0/2.5% skimmed milk/2% polyvinyl pyrrolidone/10%
goat serum/0.1% BSA/1% Tween 20/0.5 M KCl) at 37°C,
for 45 minutes. Plates were washed and incubated with
100 μl of anti-human IgG-HRP conjugate (diluted
1:10,000 in IgG assay diluent) at 37°C, for 30 minutes.
Next, wells were incubated with 100 μl of TMB soluble
substrate at 37°C, for 15 minutes. The reaction was
stopped by adding 100 μl of 1 M H2SO4 and the absor-
bance read at 450 nm. The IgM indirect ELISA was
essentially similar, except for the following differences.
Sera were diluted 1:80 in IgM assay diluent (IgG assay
diluents lacking goat serum and KCl) and pre-incubated
with Serion Rf-Absorbent as recommended by the man-
ufacturer (Virion/Serion GmbH, Würzburg, Germany)
to remove IgG antibodies before using in the assay.
Bound anti-DENV IgM antibodies were detected using
anti-human IgM-HRP conjugate (diluted 1:2,500 in IgM
assay diluent). In some experiments, the sera were tested
on streptavidin ELISA plates coated with 100 μl of
b-EDIII-T antigen (250 ng/ml, in 1x PBS, pH 7.0/0.5%
Tween 20/1% skim milk) for 2 hours, at 30°C, with shak-
ing, at 200 rpm. Wells were washed and used for IgG and
IgM indirect ELISAs as above. For each of the ELISAs
performed, the mean absorbance of the DENV IgM-/IgG-
serum samples (n = 72) plus three times the standard
deviation was designated as the cut-off value (see foot-
notes to Tables 1 and 2). We used this relatively stringent
cut-off to minimize the possibility of picking up false
positives. Results were expressed as signal to cut-off
(S/Co) ratios. Sera with S/Co ratios ≥ 1.0 were designated
as positive and those with ratios < 1 as negative.
Statistical analyses
To compare the performance of the single tetravalent
EDIII-T antigen with that of a mixture of the monovalent
EDIII antigens in detecting anti-DENV antibodies, the
S/Co values were used to calculate a ratio by dividing the
S/Co value obtained using EDIII-T antigen by the S/Co
value obtained using the EDIII monovalent antigen mix-
ture. Similarly, the performance of b-EDIII-T in strepta-
vidin-coated ELISA plates versus polystyrene plates was
assessed from a ratio of the corresponding S/Co values.
The significance of the relative sensitivity was assessed by
obtaining the 95% confidence interval (CI) using an alpha
value of 0.05, the calculated standard deviation and the
sample size. Statistical calculations were performed using
MS Excel 2003 software.
Results
Comparison of EDIII antigen mixture versus a single
chimeric EDIII-T antigen in indirect ELISAs
The reactivity of an antigen mixture comprising the
EDIIIs of the four DENV serotypes towards anti-DENV
antibodies was compared to that of a single tetravalent
antigen incorporating all these four EDIIIs in a single
molecule [5]. For this purpose indirect IgM and IgG
ELISAs were performed using 164 human sera collected
from endemic and non-endemic countries which were
pre-characterized for the presence or absence of anti-
DENV IgM and IgG antibodies using a commercial kit
from PanBio Diagnostics. As the cut-off absorbance
values for different antigens were different for the same
class antibodies (Tables 1 and 2), results are represented
as S/Co ratios to interpret the data correctly (Figure 1).
The data reveal that, both the sensitivity and specificity
of a physical mixture of 4 monovalent EDIII antigens in
detecting anti-DENV antibodies are comparable to those
obtained using the single EDIII-T antigen. In fact, the
EDIII-T antigen resulted in a modest, yet significant
increase in sensitivity (Table 1). The S/Co ratios for
DENV positive samples tended to be slightly higher in
EDIII-T based ELISAs (compare Figure 1A with 1B for
IgG and 1E with 1F for IgM).
Determination of the effect of oriented immobilization of
the tetravalent antigen in indirect ELISA
It has been suggested that specific immobilization of
antigen on the ELISA plate well can improve the
Table 1 Comparison of EDIII-based monovalent antigen mixture and single tetravalent antigen in anti-DENV antibody
detectiona
IgG (n = 80) IgM (n = 81)
Parameter EDIII Mix EDIII-T Mean Ratio of S/Co
values (95% CI)b
EDIII Mix EDIII-T Mean Ratio of S/Co
values (95% CI)b
% Sensitivityc 81.3 82.5 1.22 (1.15-1.29) 59.3 63.0 1.11 (1.06-1.16)
% Specificityd 100 100 - 100 100 -
aAssays were done using polystyrene microtiter wells that were coated either with a mixture of four EDIII monovalent antigens (EDIII Mix) or the single
tetravalent antigen, EDIII-T. The number of sera analyzed is denoted by n.
bThis column represents the mean ratio of S/Co values using EDIII-T to S/Co values using EDIII Mix as the coating antigens; the cut-off values were 0.30 and 0.33
for EDIII mix and EDIII-T, respectively, in the IgG assay, and 0.23 and 0.25, respectively, in the IgM assay. The 95% confidence interval is indicated in parentheses.
cPercent Sensitivity = (Number of sera that scored positive by our test/Number of sera that scored positive using PanBio ELISAs) × 100.
dPercent Specificity = (Number of sera that scored negative by our test/Number of sera that scored negative using PanBio ELISAs) × 100.
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performance of the immunoassay compared to passive
coating of antigen [9-11]. To test if this may be true for
the detection of anti-DENV antibodies using the tetrava-
lent antigen, we used a biotinylated version of this anti-
gen to achieve specific and oriented immobilization on
streptavidin treated ELISA plates. This demonstrated
that, indeed, b-EDIII-T coated on streptavidin plates
was superior in sensitivity in comparison to passively
coated non-biotinylated EDIII-T antigen in detecting
IgG as well as IgM antibodies (compare Figure 1B with
1D for IgG; and 1F with 1H for IgM; p < 0.05 in both
cases). This enhancement in assay sensitivity was not
evident if the b-EDIII-T antigen was passively coated on
polystyrene plates (compare Figure 1B with 1C for IgG;
and 1F with 1G for IgM). The data in Table 2 show that
the use of b-EDIII-T coated on streptavidin can enhance
the efficiency of detection of both IgG and IgM anti-
DENV antibodies, as evidenced by 30% increase in the
mean S/Co values.
Discussion
This study was undertaken to investigate if the antigenic
epitopes on the chimeric tetravalent EDIII-T antigen are
available and accessible to anti-DENV antibodies. To
this end, the ELISA reactivity of a physical mixture of
the 4 EDIII antigens was compared to that of the EDIII-
T antigen using a panel of 164 human sera that were
pre-screened with a battery of commercially available
tests for DENV, TBEV, Chikungunya virus, Plasmodium,
Leptospira, and Salmonella. The lower specificity of the
commercial Dengue IgG/IgM capture ELISA (PanBio
Diagnostics), which served as a reference in this study,
is well documented [12]. An assessment of the true sen-
sitivity of the EDIII-based assays described here was pre-
cluded due to non-availability of adequate sera for
characterization by virus neutralization tests. However,
this does not adversely affect the conclusions of this
study as it compares the relative performance of the tet-
ravalent EDIII-T antigen against a mixture of monova-
lent EDIIIs and evaluates the effect of using biotinylated
versus non-biotinylated EDIII-T in detecting serum
anti-DENV antibodies.
In both IgM and IgG indirect ELISAs the sensitivities
manifested a small but significant improvement when the
coating antigen was the single tetravalent antigen com-
pared to the physical mixture of four EDIIIs (Table 1).
Thus, this analysis showed that the individual EDIII com-
ponents are well displayed in the EDIII-T antigen. We
also found that biotinylation of the tetravalent antigen
enhanced the efficiency of anti-DENV antibody detection
further, by 30%, when it was immobilized on streptavi-
din-treated, but not on untreated surface. Further, this
enhancement was statistically significant (Table 2). Addi-
tionally, the amount of biotinylated antigen (25 ng per
well) required was a fraction of that of its non-biotiny-
lated counterpart (300ng/well). This is presumably a
reflection of better availability of the b-EDIII-T antigen
stemming from its orderly and oriented immobilization
through its biotinyl moiety to the streptavidin surface.
This is consistent with the notion that passive, random
coating on polystyrene surfaces offers only a small frac-
tion of the antigen for interaction with antibodies [10].
Using b-EDIII-T coated on streptavidin surface, the sen-
sitivity of the IgG-ELISAs was ~91% (Table 2). In the IgM
assay, sera were pre-cleared with rheumatoid factor absor-
bents to eliminate possible IgG interference. Yet, sensitiv-
ity of IgM detection was consistently lower and the
maximum that could be achieved was ~75% (Table 2).
The observation that the results of EDIII-T based ELISAs
were slightly better than those obtained with the mixture
of EDIIIs argues against the possibility that the tetravalent
design may have contributed to the lower sensitivity.
A more likely possibility is that natural DENV infections
generate a complex polyclonal response targeting a whole
range of viral epitopes with EDIII-specific antibodies com-
prising only a small proportion of the total anti-DENV
antibody population [13].
A recently reported comparative analysis of several
commercial DENV IgM antibody ELISAs has shown
that most of these suffer from low specificity, with sera
from a large percentage of malaria- and leptospirosis-
positive individuals scoring positive for anti-DENV IgM
antibodies [12]. To address the issue of false positives,
we included in our study a collection of 39 DENV
IgM-/IgG- sera that were positive for infection by several
other pathogens such as Plasmodium, Leptospira, Sal-
monella, TBEV and Chikungunya virus. Regardless of
whether we used EDIII monovalent antigen mixture or
either version of the tetravalent antigen, all these
Table 2 The performance of b-EDIII-T as a capture
antigen in the detection of anti-DENV antibodiesa
IgG (n = 80) IgM (n = 81)
Parameter PS SA Mean Ratio of
S/Co
values (95%
CI)b
PS SA Mean Ratio of
S/Co
values (95%
CI)b
%
Sensitivityc
82.5 91.3 1.32 (1.24-1.39) 61.7 75.3 1.30 (1.23-1.37)
%
Specificityd
100 100 - 100 100 -
aAssays were done using polystyrene (PS) microtiter wells or streptavidin (SA)
coated microtiter wells. The number of sera analyzed is denoted by n.
bThis column represents the mean ratio of S/Co values using SA plates to S/
Co values using PS plates; the cut-off values were 0.31 and 0.28 for PS and
SA, respectively, in the IgG assay, and 0.23 and 0.25, respectively, in the IgM
assay. The 95% confidence interval is indicated in parentheses.
cPercent Sensitivity = (Number of sera that scored positive by our test/
Number of sera that scored positive using PanBio ELISAs) × 100.
dPercent Specificity = (Number of sera that scored negative by our test/
Number of sera that scored negative using PanBio ELISAs) × 100.
Batra et al. BMC Infectious Diseases 2011, 11:64
http://www.biomedcentral.com/1471-2334/11/64
Page 4 of 6
39 sera were scored as negative samples in both IgM
and IgG ELISAs (Figure 1). The level of observed speci-
ficity may stem from the EDIII epitopes predominantly
recognizing the DENV complex, thereby reducing cross
reactivity from antibodies elicited by other non-DENV
pathogens.
Conclusions
The multiepitope antigen design coupled with the
requirement of very low quantity per assay has potential
cost benefit. However, the sensitivity needs to be
enhanced further, presumably by the inclusion of addi-
tional DENV specific epitopes. The EDIII based ELISAs
may be useful in epidemiological surveillance and vaccine
efficacy trials.
List of abbreviations
DENV: Dengue virus; EDIII: Envelope domain III; ELISA: Enzyme-linked
immunosorbent assay; HRP: Horseradish peroxisade; TBEV: Tick-borne
encephalitis virus; TMB: 3, 3’, 5, 5’-Tetramethylbenzidine.
Acknowledgements
Authors thank Dr. Amita Agarwal from Sanjay Gandhi Post Graduate
Institute, Lucknow, India and Dr. Raija Vainionpää from the Department of
Virology, University of Turku, Turku, Finland, for providing human sera
samples. This work was supported by a grant from the Department of
Biotechnology, Govt. of India.
Authors’ contributions
GB, SKN and PT performed the experiments. SS and NK conceived the study
and wrote the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 25 August 2010 Accepted: 15 March 2011
Published: 15 March 2011
References
1. Gubler DJ, Kuno G, Markoff L: Flaviviruses. In Fields Virology. 5 edition.
Edited by: Knipe DM, Howley PM. Philadelphia, Wolters Kluwer and
Lippincott Williams 2007:1153-252.
2. Swaminathan S, Khanna N: Dengue: recent advances in biology and
current status of translational research. Curr Mol Med 2009, 9:152-173.
3. Simmons M, Porter KR, Escamilla J, Graham R, Watts DM, Eckels KH,
Hayes CG: Evaluation of recombinant dengue viral envelope B domain
Serum Number
0         60     120    180  0        60      120    180 0      60      120   180 0        60      120    180
A B C D
E F G H
Figure 1 Comparative analysis of DENV-specific antibodies in patient sera in indirect ELISAs using DENV EDIII-based coating antigens.
Anti-DENV IgG (panels A-D) and IgM (panels E-H) antibodies were detected using a mixture of four monovalent EDIIIs (panels A & E), EDIII-T
(panels B & F), or b-EDIII-T (panels C, D, G & H) as the coating antigen. The antigens were coated on either polystyrene (panels A, B, C, E, F & G)
or streptavidin (panels D & H) plates. The S/Co values of individual DENV-positive and -negative sera, clustered together, are indicated by filled
and unfilled circles, respectively. The horizontal line in each panel indicates the cut-off corresponding to S/Co ratio of 1.
Batra et al. BMC Infectious Diseases 2011, 11:64
http://www.biomedcentral.com/1471-2334/11/64
Page 5 of 6
protein antigens for the detection of dengue complex-specific
antibodies. Am J Trop Med Hyg 1998, 58:144-151.
4. Ludolfs D, Schilling S, Altenschmidt J, Schmitz H: Serological differentiation
of infections with dengue virus serotypes 1 to 4 using recombinant
antigens. J Clin Microbiol 2002, 40:4317-4320.
5. Hapugoda MD, Batra G, Abeyewickreme W, Swaminathan S, Khanna N:
Single antigen detects both immunoglobulin M (IgM) and IgG
antibodies elicited by all four dengue virus serotypes. Clin Vac Immunol
2007, 14:1505-1514.
6. Guzman MG, Hermida L, Bernardo L, Ramirez R, Guillén G: Domain III of
the envelope protein as a dengue vaccine target. Expert Rev Vaccines
2010, 9:137-147.
7. Khanam S, Etemad B, Khanna N, Swaminathan S: Induction of neutralizing
antibodies specific to dengue virus serotypes 2 and 4 by a bivalent
antigen composed of linked envelope domains III of these two
serotypes. Am J Trop Med Hyg 2006, 74:266-277.
8. Batra G, Talha SM, Nemani SK, Dhar N, Swaminathan S, Khanna N:
Expression, purification and characterization of in vivo biotinylated
dengue virus envelope domain III based tetravalent antigen. Prot Exp
Purif 2010, 74:99-105.
9. Schetters H: Avidin and streptavidin in clinical diagnostics. Biomol Eng
1999, 16:73-78.
10. Butler JE: Solid supports in enzyme-linked immunosorbent assay and
other solid-phase immunoassays. Methods 2000, 22:4-23.
11. Nakanishi K, Sakiyama T, Kumada Y, Imamura K, Imanaka H: Recent
advances in controlled immobilization of proteins onto the surface of
the solid substrate and its possible application to proteomics. Curr
Proteomics 2008, 5:161-175.
12. Hunsperger EA, Yoksan S, Buchy P, Nguyen VC, Sekaran SD, Enria DA,
Pelegrino JL, Vázquez S, Artsob H, Drebot M, Gubler DJ, Halstead SB,
Guzmán MG, Margolis HS, Nathanson CM, Lic NRR, Bessoff KE, Kliks S,
Peeling RW: Evaluation of commercially available anti-dengue virus
immunoglobulin M tests. Emerg Infect Dis 2009, 15:436-440.
13. Wahala WMPB, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM:
Dengue virus neutralization by human immune sera: role of envelope
protein domain III-reactive antibody. Virology 2009, 392:103-113.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2334/11/64/prepub
doi:10.1186/1471-2334-11-64
Cite this article as: Batra et al.: Evaluation of envelope domain III-based
single chimeric tetravalent antigen and monovalent antigen mixtures
for the detection of anti-dengue antibodies in human sera. BMC
Infectious Diseases 2011 11:64.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Batra et al. BMC Infectious Diseases 2011, 11:64
http://www.biomedcentral.com/1471-2334/11/64
Page 6 of 6
